Targeting IDH2^R140Q and Other Neoantigens in Acute Myeloid Leukemia

Researchers explored the feasibility of immunotherapeutically targeting neoantigens, which arise from recurrent non-synonymous mutations in AML, and thus represent attractive targets since they are exclusively present on the tumor.